Grafa News and Videos — Page 1000

In a significant move for pharmaceutical transparency, the Bristol Myers Squibb-Pfizer Alliance announced that Eliquis® (apixaban), one of the world’s most widely prescribed blood thinners, will soon be available through Mark Cuban’s direct-to-consumer pharmacy.

Ponce Financial Group (NASDAQ:PDLB) reported a profitable start to 2026, characterized by a double-digit rise in shareholder equity and a stable interest margin that underscores the lender’s successful navigation of the current rate environment.

The Western Union Company (NYSE:WU) reported mixed first-quarter results as the legacy remittance giant works to offset retail headwinds in the Americas through an aggressive digital expansion and a foray into blockchain-native payment systems.

ChoiceOne Financial Services NASDAQ:COFS) reported a strong start to 2026, driven by a significant expansion in its net interest margin and robust organic deposit growth that fortified the community bank’s balance sheet.

WiMi Hologram Cloud (NASDAQ:WIMI) reported a massive surge in annual profitability for 2025, underscoring a successful transition toward leaner operations and a significantly fortified balance sheet.

HCA Healthcare (NYSE:HCA) posted a solid start to 2026, delivering a double-digit increase in earnings per share as steady patient volumes and operational "resiliency" initiatives helped the hospital giant navigate a complex reimbursement landscape.

Charter Communications (NASDAQ:CHTR) reported a slight dip in first-quarter revenue and earnings, as record-breaking growth in its mobile segment struggled to fully compensate for a cooling residential broadband market.

The Procter & Gamble Company (NYSE:PG) reported a robust rise in third-quarter sales and earnings, underpinned by steady consumer demand and a strategic portfolio adjustment that provided a significant boost to the bottom line.

SLB reported a slight increase in first-quarter revenue, but the world’s largest oilfield services provider saw its earnings retreat as production disruptions in the Middle East pressured operational margins and dampened bottom-line performance.

Merck (NYSE:MRK) has moved a step closer to finalizing its multi-billion dollar bet on the next generation of blood cancer treatments, clearing a key federal antitrust review for its acquisition of Terns Pharmaceuticals.